Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Scott Power: S&P/ASX 200 Health Care Index falls but which stocks are up on positive news?
Health & Biotech
NUZ inks positive opinion on orphan product designation for NUZ-001 in Europe
Health & Biotech
Spark Plus sees 225pc upside in biotech player Neurizon
Health & Biotech
Neurizon’s strong September quarter to propel treatments for neurodegenerative diseases forward
Stockhead TV
Long Shortz with Neurizon Therapeutics: Goodbye to PharmAust, hello to neuro horizons
Health & Biotech
PharmAust rebrands as Neurizon Therapeutics as it pioneers treatment for neurodegenerative diseases
Health & Biotech
Dr Boreham’s Crucible: Can this small company meet MND drug development’s sizeable need?
News
Closing Bell: ASX up but MinRes slumps on lithium downgrade; China stocks also sink
Stockhead TV
Long Shortz with PharmAust: Sweet incentives for sad disease’s drug development
Health & Biotech
Health Kick Podcast: PharmAust in the fight against MND and ALS with lead drug monepantel
The Ethical Investor: Falling birth rates propel pets sector, and why ESG investors should tap into it
Health & Biotech
ASX stocks leading clinical trials in Australia
News
Closing Bell: ASX choppy as traders sit it out; BPM soars on Mt Gibson gold find
Health & Biotech
PharmAust seeks orphan drug designation in Europe for monepantel to treat ALS
Health & Biotech
Morgans sees big upside for PharmAust if monepantel succeeds
Health & Biotech
PharmAust reports positive interim results of OLE study on monepantel to treat ALS
Health & Biotech
